Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Curr Opin Oncol. 2010 May;22(3):236-41. doi: 10.1097/cco.0b013e3283384181.
To discuss several important developments in testicular germ cell tumors in the past year.
Genomic studies are examining gene expression as possible markers for disease relapse and chemotherapy resistance. Optimal treatment strategies for early-stage nonseminomatous tumors continue to evolve and patient compliance with posttreatment surveillance schedules remains problematic. Advanced and platinum-refractory disease states continue to be challenging entities in terms of optimizing therapy and outcome.
Significant challenges remain for treatment of certain categories of testicular germ cell tumors. Treatment and surveillance paradigms continue to be defined and refined as research in these areas continues.
讨论过去一年中睾丸生殖细胞肿瘤的几个重要进展。
基因组研究正在研究基因表达，作为疾病复发和化疗耐药的可能标志物。早期非精原细胞瘤的最佳治疗策略仍在不断发展，患者对治疗后监测计划的依从性仍然存在问题。晚期和铂类难治性疾病在优化治疗和预后方面仍然是具有挑战性的实体。
某些类型的睾丸生殖细胞肿瘤的治疗仍存在重大挑战。随着这些领域的研究不断进行，治疗和监测模式仍在不断定义和完善。
